The congress was attended by more than 800 researchers from around the World. Preclinical data of BIOGENERA’s new anti-tumor drug BGA002 were presented, and the new Phase I clinical trial for Neuroblastoma that will be initiated in the coming months was also presented. The data attracted great interest and attention.
The Congress was an opportunity to continue the many contacts, and also create new ones, with international Key Opinion Leaders, who have shown strong interest in participating in the Phase I Clinical Trial of the drug BGA002 for Neuroblastoma.
